Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,814,934)	$ (2,960,794)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation	45,630	23,313
Stock-based compensation	266,270	165,971
Bad debt expense	26,075
Loss on disposal of asset		202
Amortization of right-of-use assets	76,654	39,059
Other non-cash charges	(6,364)	(3,139)
Changes in operating assets and liabilities:
Accounts receivable	272,748	169,642
Inventories	(229,740)	(86,677)
Prepaid expenses and other current assets	(142,240)	(426,515)
Other assets	(16,079)
Accounts payable and accrued expenses	294,828	952,339
Operating Lease Liabilities	(97,098)	21,040
Deferred revenue	1,650	(2,512)
Other liabilities		(4,637)
Net cash used in operating activities	(2,322,600)	(2,112,708)
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in Jiangxi Myomo Medical Assistive Appliance Co. Ltd.	(199,000)
Purchases of equipment	(49,879)	(44,489)
Net cash used in investing activities	(248,879)	(44,489)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants		7,288,275
Net cash provided by financing activities		7,288,275
Effect of foreign exchange rate changes on cash	(10,392)	(1,122)
Net (decrease) increase in cash, cash equivalents and restricted cash	(2,581,871)	5,129,956
Cash, cash equivalents and restricted cash, beginning of period	15,524,378	12,241,261
Cash, cash equivalents and restricted cash, end of period	12,942,507	17,371,217
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Right of use assets obtained in exchange for lease liabilities	$ 225,665	654,091
Property and equipment included in accounts payable and in accrued expenses and other liabilities		$ 94,298